ArticleCentral European journal of urology2024
Outcomes and predictors of clinically significant prostate cancer detection by transperineal computer fusion biopsy during active surveillance.
Article in Central European journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Active surveillance (AS) is an option for management of low-risk and selected intermediate prostate cancer (PC) patients. Pathological progression confirmed on prostate biopsy (PB) is the most common reason for transitioning to radical treatment. The role and timing of repeat PB during AS is a topic of ongoing debate.The aim of the study was to determine the detection rate of clinically significant PC (csPC) during AS protocol by transperineal computer fusion PB in low-risk PC patients enrolled based on results of transrectal systematic PB, and to identify predictors that may impact csPC detection. Material and methods: The study involved 95 patients with low-risk PC enrolled in AS, who underwent confirmatory or follow-up PB, proceeded by mpMRI. Results: The reclassification rate to csPC was 38.9% and 43.9% for confirmatory and follow-up biopsies, respectively. Patients with csPC differed significantly from those without csPC in the following parameters: prostate-specific antigen (PSA) 10.5 ng/ml vs 7.3 ng/ml (p = 0.029), PSA density (PSAD) 0.27 ng/ml Conclusions: Confirmatory and repeat transperineal PB detect a significant rate of csPC in low-risk PC patients on AS. Higher PIRADS score and PSAD >0.20 ng/ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.